{"organizations": [], "uuid": "8607ca8120e0003e6aee155d389fb71a9424555e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/08/globe-newswire-neos-therapeutics-to-host-fourth-quarter-and-year-end-2017-financial-results-conference-call-on-march-15-2017.html", "country": "US", "domain_rank": 767, "title": "Neos Therapeutics to Host Fourth Quarter and Year-End 2017 Financial Results Conference Call on March 15, 2017", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.006, "site_type": "news", "published": "2018-03-08T15:30:00.000+02:00", "replies_count": 0, "uuid": "8607ca8120e0003e6aee155d389fb71a9424555e"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/08/globe-newswire-neos-therapeutics-to-host-fourth-quarter-and-year-end-2017-financial-results-conference-call-on-march-15-2017.html", "ord_in_thread": 0, "title": "Neos Therapeutics to Host Fourth Quarter and Year-End 2017 Financial Results Conference Call on March 15, 2017", "locations": [], "entities": {"persons": [], "locations": [{"name": "fort worth", "sentiment": "none"}, {"name": "texas", "sentiment": "none"}, {"name": "dallas", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "neos therapeutics, inc.", "sentiment": "neutral"}, {"name": "neos therapeutics neos therapeutics, inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "DALLAS and FORT WORTH, Texas, March 08, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that it will report fourth quarter and year-end 2017 financial results prior to the opening of U.S. financial markets on Thursday, March 15, 2017. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.\nThe live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 5653457. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/ .\nAbout Neos Therapeutics\nNeos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT ® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information , including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information , including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information , including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. Additional information about Neos is available at www.neostx.com .\nContacts:\nRichard Eisenstadt\nChief Financial Officer\nNeos Therapeutics\n(972) 408-1389\nreisenstadt@neostx.com\nSarah McCabe\nSenior Vice President\nStern Investor Relations, Inc.\n(212) 362-1200\nsarah@sternir.com\nSource:Neos Therapeutics, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=-xL8B6WMSIg_c6fuIvPPAOBKsipcsQILnk4-dZ3QVMCkd05jS8b9zo_y3Wvp_ke7ukhwLxZF0C6Y56hL_u0ylLnuTq_JCDZ-RTiI2d7dT_A=", "https://www.globenewswire.com/Tracker?data=PiLfuFlDqGUiqOT8kmy_pTusJ9OLpCnuyNWLdciYK6BmbV44tuy-J6-5aRqMtg6WGFSrIWlWH1i2jLxYkuyQFw==", "https://www.globenewswire.com/Tracker?data=4BxOwsUMpU8J5zxepfC8ZhuOoaaktajx32-LOpvG3IeS8GpqDBKTA_tBa68VGAgFoPlhdbJn4uVak-MYgIohqGTjp-ojmuE4CVaYyPHByPI=", "http://investors.neostx.com/", "https://www.globenewswire.com/Tracker?data=HRsSeErRYoh-IUAdhlQYCJNRPKFGp1BWruHvbTfhHUIcwVQ7aIutbZRKdkQSRnhg1a3CzZLo1hFDZZw-KBrhCBoboMw6Y2foKAYhZ2uNOnQ6u7Hznq1Ep6zVWu3rdemtAPX0wzxmtMgIgTvOeN3mGp1n2worH64reUDY9alnim4=", "https://www.globenewswire.com/Tracker?data=Yvg4GFGZ0kBLrXgTC09SKTVO6q2LzccIzTycWll0cyUdxoSnNlwSp4LExgwTUbCfBxx5F8Wqc45lLig9vRmGqQ==", "https://www.globenewswire.com/Tracker?data=HRsSeErRYoh-IUAdhlQYCJNRPKFGp1BWruHvbTfhHUJ0LMRuaAif9h2ZMyGzBD9n4PFH48F-zZd7jBZaCRPLrCk_WdS3IyboZOljZG5e3tkw3oCWRcE5YwkvPvOlkLmkPpqlrFu3l5SCbhvbJZClNQ==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/f2ff2f0a-adaf-45b6-8260-69343b572ad1", "https://www.globenewswire.com/Tracker?data=HRsSeErRYoh-IUAdhlQYCJNRPKFGp1BWruHvbTfhHUJmPHWVj1sutVGhuN50lYoHuxDSHlT0szzXeZX2WIhOz4xG7WhebB_DhB1EsUzoFdRcuVZRztycJqw59XqAW8SewHF-he8B7C75iAcxQd8XPw=="], "published": "2018-03-08T15:30:00.000+02:00", "crawled": "2018-03-08T16:24:26.022+02:00", "highlightTitle": ""}